These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 1161676)

  • 21. o,p'-DDD (mitotane) treatment for Cushing's syndrome: adrenal drug concentration and inhibition in vitro of steroid synthesis.
    Touitou Y; Moolenaar AJ; Bogdan A; Auzéby A; Luton JP
    Eur J Clin Pharmacol; 1985; 29(4):483-7. PubMed ID: 4092727
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The medical treatment of Cushing's syndrome.
    Miller JW; Crapo L
    Endocr Rev; 1993 Aug; 14(4):443-58. PubMed ID: 7693447
    [No Abstract]   [Full Text] [Related]  

  • 23. [Treatment of Cushing's syndrome and adrenal cancer with O,p-DDD].
    Kinouchi T; Shimizu N; Ibayashi H; Demura H; Oshima H
    Horumon To Rinsho; 1982 Aug; 30(8):841-51. PubMed ID: 7139984
    [No Abstract]   [Full Text] [Related]  

  • 24. Virilizing adrenal tumor in a child suppressed with dexamethasone for three years. Effect of o,p'-DDD on serum and urinary androgens.
    Korth-Schutz S; Levine LS; Roth JA; Saenger P; New MI
    J Clin Endocrinol Metab; 1977 Mar; 44(3):433-9. PubMed ID: 138687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. o,p'--DDD and adrenal carcinoma.
    McKiernan P; Doyle DA; Duffy GJ; Towers RP; Duff FA; O'Donovan DK
    Ir J Med Sci; 1978 Dec; 147(12):437-40. PubMed ID: 730493
    [No Abstract]   [Full Text] [Related]  

  • 26. Complete response of metastatic adrenal cortical carcinoma to o,p'-DDD in a child.
    Krzisnik C; Petric G; Jereb B
    Pediatr Hematol Oncol; 1988; 5(1):65-9. PubMed ID: 3152953
    [No Abstract]   [Full Text] [Related]  

  • 27. [Cancer of the adrenal cortex treated by O,P"-DDD (author's transl)].
    Van Geertruyden J; De Myttenaere M; Corvilain J
    Acta Chir Belg; 1980; 79(4):299-302. PubMed ID: 7468032
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinico-hormonological study of the effects of aminoglutethimide in a case of adrenal cortex carcinoma].
    Rolandi E; Bianchi G
    Arch Maragliano Patol Clin; 1971; 27(5):223-32. PubMed ID: 5172809
    [No Abstract]   [Full Text] [Related]  

  • 29. AN EFFECT OF O,P'-DDD ON THE EXTRA-ADRENAL METABOLISM OF CORTISOL IN MAN.
    BLEDSOE T; ISLAND DP; NEY RL; LIDDLE GW
    J Clin Endocrinol Metab; 1964 Dec; 24():1303-11. PubMed ID: 14243174
    [No Abstract]   [Full Text] [Related]  

  • 30. o,p'-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacement.
    Hogan TF; Citrin DL; Johnson BM; Nakamura S; Davis TE; Borden EC
    Cancer; 1978 Nov; 42(5):2177-81. PubMed ID: 719602
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comment--Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma?
    Barzon L; Fallo F; Sonino N; Daniele O; Boscaro M
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1488-9. PubMed ID: 10199802
    [No Abstract]   [Full Text] [Related]  

  • 32. [Hemorrhage into the peritoneum in the course of treatment of adrenocortical carcinoma with o,p'-DDD and 5-fluorouracil].
    Kasperlik-Zaluska A; Migdalska B
    Endokrynol Pol; 1976; 27(1):111-5. PubMed ID: 1253752
    [No Abstract]   [Full Text] [Related]  

  • 33. Aminoglutethimide in the treatment of Cushing's syndrome.
    Misbin RI; Canary J; Willard D
    J Clin Pharmacol; 1976; 16(11-12):645-51. PubMed ID: 993360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Regression under the influence of OP'DDD of a malignant cortico-adrenaloma and of its metastases (author's transl)].
    Charbonnel B; Guillon J; Chupin M
    Nouv Presse Med; 1980 Jan; 9(4):239-41. PubMed ID: 7383883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cushing's syndrome associated with a bronchial adenoma. Possible periodic hormonogenesis.
    Shapiro MS; Gutman A; Bruderman I; Myers B; Griffel WB
    Isr J Med Sci; 1975 Sep; 11(9):919-24. PubMed ID: 1184365
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metastatic adrenal cortical carcinoma: biochemical changes accompanying clinical regression during therapy with o,p'-DDD.
    Helson L; Wollner N; Murphy ML; Schwartz MK
    Clin Chem; 1971 Dec; 17(12):1191-3. PubMed ID: 4330217
    [No Abstract]   [Full Text] [Related]  

  • 37. Adrenocortical carcinoma responded to treatment with o,p'-DDD--a case report.
    Naruse T; Koike A; Kato K; Ishii T; Suzumura K; Matsumoto K
    Endocrinol Jpn; 1984 Aug; 31(4):417-26. PubMed ID: 6097439
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recovery of adrenal function after treatment of adrenocortical carcinoma with o,p'-DDD.
    Greig F; Oberfield SE; Levine LS; Ghavimi F; Pang S; New MI
    Clin Endocrinol (Oxf); 1984 Apr; 20(4):389-99. PubMed ID: 6325050
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Studies in a patient with an ectopic adrenocortical tumor.
    Ney RL; Hammond W; Wright L; Davis WW; Acker J; Bartter FC
    J Clin Endocrinol Metab; 1966 Mar; 26(3):299-304. PubMed ID: 4286018
    [No Abstract]   [Full Text] [Related]  

  • 40. Fine structural and biochemical effects of aminoglutethimide and o,p'-DDD on rat adrenocortical carcinoma 494 and adrenals.
    Moore RN; Penney DP; Averill KT
    Anat Rec; 1980 Sep; 198(1):113-24. PubMed ID: 7457928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.